GB2542192A - Chewable medicament - Google Patents
Chewable medicament Download PDFInfo
- Publication number
- GB2542192A GB2542192A GB1516153.2A GB201516153A GB2542192A GB 2542192 A GB2542192 A GB 2542192A GB 201516153 A GB201516153 A GB 201516153A GB 2542192 A GB2542192 A GB 2542192A
- Authority
- GB
- United Kingdom
- Prior art keywords
- chewing gum
- gum composition
- chewing
- gum
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title description 10
- 235000015218 chewing gum Nutrition 0.000 claims abstract description 194
- 229940112822 chewing gum Drugs 0.000 claims abstract description 185
- 239000000203 mixture Substances 0.000 claims abstract description 155
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 52
- 239000003765 sweetening agent Substances 0.000 claims abstract description 52
- 239000004480 active ingredient Substances 0.000 claims abstract description 43
- 239000000796 flavoring agent Substances 0.000 claims abstract description 36
- 238000007906 compression Methods 0.000 claims abstract description 35
- 230000006835 compression Effects 0.000 claims abstract description 35
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 20
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 50
- 229960002715 nicotine Drugs 0.000 claims description 46
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 43
- 229920001971 elastomer Polymers 0.000 claims description 37
- 239000000806 elastomer Substances 0.000 claims description 36
- 230000001055 chewing effect Effects 0.000 claims description 34
- -1 dried invert sugar Substances 0.000 claims description 32
- 239000000945 filler Substances 0.000 claims description 32
- 239000008123 high-intensity sweetener Substances 0.000 claims description 27
- 235000013615 non-nutritive sweetener Nutrition 0.000 claims description 27
- 239000004014 plasticizer Substances 0.000 claims description 27
- 239000006188 syrup Substances 0.000 claims description 27
- 235000020357 syrup Nutrition 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 25
- 229920002367 Polyisobutene Polymers 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000003963 antioxidant agent Substances 0.000 claims description 20
- 235000006708 antioxidants Nutrition 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- 229920002554 vinyl polymer Polymers 0.000 claims description 20
- 239000003995 emulsifying agent Substances 0.000 claims description 19
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- 231100000252 nontoxic Toxicity 0.000 claims description 18
- 230000003000 nontoxic effect Effects 0.000 claims description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 15
- 229960004793 sucrose Drugs 0.000 claims description 15
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 14
- 229930013930 alkaloid Natural products 0.000 claims description 14
- 239000013536 elastomeric material Substances 0.000 claims description 14
- 229960002737 fructose Drugs 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 9
- 108010011485 Aspartame Proteins 0.000 claims description 9
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 9
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 9
- 239000004376 Sucralose Substances 0.000 claims description 9
- 239000000619 acesulfame-K Substances 0.000 claims description 9
- 239000000605 aspartame Substances 0.000 claims description 9
- 235000010357 aspartame Nutrition 0.000 claims description 9
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 9
- 229960003438 aspartame Drugs 0.000 claims description 9
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 9
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 9
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 9
- 239000011736 potassium bicarbonate Substances 0.000 claims description 9
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 9
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 9
- 235000011181 potassium carbonates Nutrition 0.000 claims description 9
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 9
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 9
- 235000017550 sodium carbonate Nutrition 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 235000019408 sucralose Nutrition 0.000 claims description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 239000004386 Erythritol Substances 0.000 claims description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 8
- VHOQXEIFYTTXJU-UHFFFAOYSA-N Isobutylene-isoprene copolymer Chemical compound CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- 239000008121 dextrose Substances 0.000 claims description 8
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 8
- 235000019414 erythritol Nutrition 0.000 claims description 8
- 229940009714 erythritol Drugs 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000000905 isomalt Substances 0.000 claims description 8
- 235000010439 isomalt Nutrition 0.000 claims description 8
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 8
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 8
- 235000010449 maltitol Nutrition 0.000 claims description 8
- 239000000845 maltitol Substances 0.000 claims description 8
- 229940035436 maltitol Drugs 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 229960001855 mannitol Drugs 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 229960002920 sorbitol Drugs 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 7
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 7
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 7
- 235000005822 corn Nutrition 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 235000013681 dietary sucrose Nutrition 0.000 claims description 7
- 229930182830 galactose Natural products 0.000 claims description 7
- 229960003082 galactose Drugs 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 150000002303 glucose derivatives Chemical class 0.000 claims description 7
- 229960004903 invert sugar Drugs 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 229960001375 lactose Drugs 0.000 claims description 7
- 229960002160 maltose Drugs 0.000 claims description 7
- 150000003505 terpenes Chemical class 0.000 claims description 7
- 235000007586 terpenes Nutrition 0.000 claims description 7
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 7
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 230000018984 mastication Effects 0.000 claims description 6
- 238000010077 mastication Methods 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000011118 polyvinyl acetate Substances 0.000 claims description 5
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004902 Softening Agent Substances 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- 235000015111 chews Nutrition 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 claims description 3
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 claims description 3
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 claims description 3
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 claims description 3
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 claims description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 3
- 229930006722 beta-pinene Natural products 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002168 ethanoic acid esters Chemical class 0.000 claims description 3
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 claims description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 3
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 claims description 2
- YAXKTBLXMTYWDQ-UHFFFAOYSA-N 1,2,3-butanetriol Chemical compound CC(O)C(O)CO YAXKTBLXMTYWDQ-UHFFFAOYSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 2
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004377 Alitame Substances 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 229920001412 Chicle Polymers 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 240000000896 Dyera costulata Species 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 239000000899 Gutta-Percha Substances 0.000 claims description 2
- 244000043261 Hevea brasiliensis Species 0.000 claims description 2
- 239000004166 Lanolin Substances 0.000 claims description 2
- 240000002636 Manilkara bidentata Species 0.000 claims description 2
- 240000001794 Manilkara zapota Species 0.000 claims description 2
- 235000011339 Manilkara zapota Nutrition 0.000 claims description 2
- 108050004114 Monellin Proteins 0.000 claims description 2
- VQENOYXMFIFHCY-UHFFFAOYSA-N Monoglyceride citrate Chemical compound OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O VQENOYXMFIFHCY-UHFFFAOYSA-N 0.000 claims description 2
- 240000000342 Palaquium gutta Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 235000019409 alitame Nutrition 0.000 claims description 2
- 108010009985 alitame Proteins 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
- 235000016302 balata Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 150000001579 beta-carotenes Chemical class 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 229940095643 calcium hydroxide Drugs 0.000 claims description 2
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- GLVVKKSPKXTQRB-UHFFFAOYSA-N ethenyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC=C GLVVKKSPKXTQRB-UHFFFAOYSA-N 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 2
- 239000004247 glycine and its sodium salt Substances 0.000 claims description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 229920000588 gutta-percha Polymers 0.000 claims description 2
- 229940039717 lanolin Drugs 0.000 claims description 2
- 235000019388 lanolin Nutrition 0.000 claims description 2
- 229920003008 liquid latex Polymers 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000869 magnesium oxide Drugs 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 229940114930 potassium stearate Drugs 0.000 claims description 2
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 229940029258 sodium glycinate Drugs 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 claims description 2
- 239000000892 thaumatin Substances 0.000 claims description 2
- 235000010436 thaumatin Nutrition 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 2
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 244000061176 Nicotiana tabacum Species 0.000 claims 1
- 239000002585 base Substances 0.000 description 90
- 238000000576 coating method Methods 0.000 description 36
- 239000011248 coating agent Substances 0.000 description 31
- 239000004615 ingredient Substances 0.000 description 21
- 210000000214 mouth Anatomy 0.000 description 18
- 235000019634 flavors Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000012384 transportation and delivery Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229940015769 nicotine chewing gum Drugs 0.000 description 8
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 6
- 241000208125 Nicotiana Species 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229920001778 nylon Polymers 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 244000215068 Acacia senegal Species 0.000 description 5
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 5
- 229920000084 Gum arabic Polymers 0.000 description 5
- 239000000205 acacia gum Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000009501 film coating Methods 0.000 description 5
- 239000007888 film coating Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical group C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- HBKBEZURJSNABK-MWJPAGEPSA-N 2,3-dihydroxypropyl (1r,4ar,4br,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)OCC(O)CO HBKBEZURJSNABK-MWJPAGEPSA-N 0.000 description 4
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 4
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 4
- 235000010634 bubble gum Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008199 coating composition Substances 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000007430 reference method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- GFJUOMJGSXRJJY-UHFFFAOYSA-N 2-methylprop-1-ene Chemical compound CC(C)=C.CC(C)=C GFJUOMJGSXRJJY-UHFFFAOYSA-N 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001738 temporomandibular joint Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- KJQMOGOKAYDMOR-UHFFFAOYSA-N CC(=C)C=C.CC(=C)C=C Chemical compound CC(=C)C=C.CC(=C)C=C KJQMOGOKAYDMOR-UHFFFAOYSA-N 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 239000008376 breath freshener Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012764 mineral filler Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940087730 nicorette Drugs 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Confectionery (AREA)
Abstract
Chewing gum compositions comprising at least one biologically active ingredient, a chewing gum base and at least one sweetening or flavouring agent are described, in which the gum compositions have a compression modulus of less than 7 kPa. The gum compositions exhibit improved patient compliance when compared with prior art gums, as well as offering improved release characteristics of the active ingredient contained therein.
Description
CHEWABLE MEDICAMENT
INTRODUCTION
[0001] The present invention relates to a chewing gum composition comprising at least one biologically active ingredient, as well as to a process for the preparation of the chewing gum composition.
BACKGROUND OF THE INVENTION
[0002] Chewing gums provide a convenient and discrete way of administering actives to the oral cavity for localised or systemic delivery. Use of chewing gum as a delivery vehicle has the advantages of rapid therapeutic action, avoidance of first-pass metabolism, comparatively long residence time in the buccal cavity, useful for localised treatment and a safe delivery system as the gum can be removed from the mouth to cease treatment, also any active will remain in the chewing gum should it be accidentally swallowed and will not be released into the body. The challenges of chewing gum as a delivery system include taste-masking of often bitter actives, the very firm chew of medicated gums, also most medicated gums only release 75% of the active in 30 minutes [see R. C. Rowe. "By gum - A buccal delivery system." Drug Discovery Today 2003:8(14): 617-618, the contents of which are incorporated by way of example]; which is a profligate use of the most expensive component of the formulation. The problem of taste-masking bitter actives released from medicated chewing gum is compounded by the often incomplete release of the flavour from the chewing gum.
[0003] The hard chew profile of medicated chewing gums can reduce patient compliance and may also damage teeth and gums; prevent use of a treatment by denture wearers and may cause jaw ache in users.
[0004] Although there are a number of medicated chewing gums commercially available there are still areas for improvement in medicated chewing gum formulation to improve the sensory aspects, which in turn may well improve patient compliance. Another area that may benefit from formulation improvements is the release of expensive components from the chewing gum that are traditionally only partially released from the gum base i.e. actives and flavours. Novel formulations could improve the consumer experience with more flavour, reduce raw material costs and potentially extend acceptance of medicated gum to people who have previously rejected use due to the hard texture such as temporomandibular joint (TMJ) disorder sufferers.
[0005] Nicotine chewing gum for smoking cessation is one of the most common forms of medicated chewing gum and there is significant prior art describing gums with modified nicotine release profiles; from mimicking the nicotine blood plasma levels achieved when smoking a cigarette (US 8,529,875 & US 8,828361), formulations that will provide rapid nicotine craving relief (US 8,524,196, US 8,858,919), formulations having a sustained release of nicotine (US 8,623,332 & US 9,028,803) and formulations that will provide an initial burst of nicotine followed by a more steady nicotine delivery (EP1107730 & CA 2346330). However, in spite of the advances made by these disclosures, the incomplete release of nicotine from chewing gums remains an unresolved problem in that a sizable amount of nicotine remains in the chewing gum after it has been chewed.
[0006] The present invention was devised with the foregoing in mind.
SUMMARY OF THE INVENTION
[0007] According to a first aspect of the present invention there is provided a chewing gum composition comprising a chewing gum base, at least one biologically active ingredient and at least one sweetening or flavouring agent, wherein the chewing gum composition has a compression modulus of less than 7 kPa.
[0008] According to a further aspect of the present invention there is provided a process for the preparation of the chewing gum composition as defined herein, the process comprising the step of: a) mixing, until homogenous, the gum base, at least one biologically active ingredient and at least one sweetening or flavouring agent.
[0009] According to a further aspect of the present invention there is provided a chewing gum composition obtainable, obtained or directly obtained by a process defined herein. DETAILED DESCRIPTION OF THE INVENTION Chewing gum compositions [0010] As discussed hereinbefore, the present invention provides a chewing gum composition comprising a chewing gum base, at least one biologically active ingredient and at least one sweetening or flavouring agent, wherein the chewing gum composition has a compression modulus of less than 7 kPa.
[0011] The present invention addresses a number of shortcomings of prior art compositions Perhaps most notably, the compositions of the present invention release substantially all of a biologically active ingredient contained therein over a 30 minute chew period. It will be understood that in the context of the present invention, the term “substantially all” means an amount greater than or equal to 85 wt% of the total quantity of biologically active ingredient contained within the composition. For example, conventionally, a 4 mg nicotine gum only releases about 3 mg or less of the contained nicotine, whereas using a chewing gum composition of the present invention would allow loading of 3 mg of nicotine into the chewing gum to achieve an equivalent delivery. Alternatively, a 4 mg nicotine gum could be formulated into a composition as described herein to deliver an increased dose of the active, comparative to 4 mg compositions of the prior art, to the user and provide more effective craving relief.
[0012] The improved release characteristics of the present compositions are conferred, at least in part, by the novel chew profile of the gum, as measured by the gum’s compression modulus. The chewing gum compositions of the present invention have a compression modulus of less than 7 kPa at all stages of the chewing profile. By chewing these compositions, the active is released from the chewing gum. Saliva coats the oral tissues under the tongue (sublingual) and the sides of the mouth where the active may partition from the saliva into the oral mucosa. It is thought that chewing creates pressure in the buccal cavity which forces the active ingredient directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly accelerates absorption of the active into the systemic system, compared to the typical gastro-intestinal routes.
[0013] The chew profile of a chewing gum measured by compression can be defined as firm (or hard), medium or soft. A hard or firm chew profile can be defined as a chewing gum with a compression modulus above or about 12 kPa. A medium chew profile can be characterised by a compression modulus with values between about 7 kPa and about 12 kPa. A soft chewing gum is defined by a compression modulus of about or less than 7 kPa. It can be envisioned that a chewing gum may not fall within a defined hardness range for the duration of a chew but be first described as a hard or firm chew at the outset and then soften with chewing to become a medium chew gum. Obviously gums may move between all grades of chew (hard to soft) during a 30 minute chew period. It is a desirable property for a chewing gum to have a consistent chew throughout the chewing period.
[0014] The chew profile of a chewing gum can be described as the firmness of the gum during chewing. The initial chewing phase consists of the first 10 to 20 seconds, it includes the first bite into the gum and the first few chews where the gum mass should stay in one piece and not crumble. The intermediate period of chewing a gum is the period where most of the flavours and sweeteners are extracted from the gum matrix, this phase starts after the initial 10 to 20 seconds and usually lasts one to three minutes for a confectionery gum, for a medicated gum that may have specific chewing instructions such as ‘park and chew’ the intermediate period may last longer than three minutes. The end of the intermediate chewing stage is reached when most of the bulk sweeteners have been extracted. During the intermediate chewing phase the gum will soften as the gum mass temperature is raised in the oral cavity, the sweeteners dissolve and the gum cud is hydrated with saliva, the ideal is to have as little change in the size and texture of the gum as possible during the entire chewing experience. The final chewing phase starts once the majority of the bulk sweeteners have been chewed out until the gum is removed from the mouth. The chewing gum may well undergo a degree of hardening compared to the intermediate phase.
[0015] In addition to the improved release properties, the gum compositions of the present invention markedly improve user compliance due to their comparatively softer chew profile. The compositions of the invention therefore carry with them a notably reduced risk of jaw ache, or damaged teeth, gum and dentures.
[0016] A further advantage conferred by the present invention is a potential reduction in pollution. A chewing gum containing a pharmaceutically active ingredient that is disposed of improperly has the potential to release the remaining active ingredients into its surroundings over time which may damage the environment or cause harm to humans and animals.
[0017] In an embodiment, the chewing gum composition has a compression modulus of less than 7 kPa at all stages during a 30 minute chewing cycle. It will be understood that most active-containing chewing gums prescribe a 30 minute chew cycle for delivery of the active. Suitably, the chewing gum composition has a compression modulus of 0.5 to 7 kPa at all stages during a 30 minute chewing cycle. More suitably, the chewing gum composition has a compression modulus of 1.5 to 6 kPa at all stages during a 30 minute chewing cycle. Most suitably, the chewing gum composition has a compression modulus of 3 to 6 kPa at all stages during a 30 minute chewing cycle.
[0018] The compression modulus (hardness) values stated herein are calculated according to the following protocol: a chewed gum cud (chewed for a predetermined amount of time) is immediately transferred to a level, non-compressible surface, covered with a wet, nylon disc and compressed using a known mass, for example by a person standing on the nylon disc covering the gum cud for 10 s. The nylon disc is removed from the gum cud and the diameter of the gum cud is measured using a calibrated vernier caliper gauge or a ruler. Ideally at least two readings of the diameter, perpendicular to each other, are recorded and averaged to give a representative indication of the compressed gum cud size. The compression modulus is calculated using the following equations: 1) radius of sphere (rs)
where: rs = radius of spherical gum cud (m)
V = volume (g) and assume density of gum cud = 1; d=m/V 2) surface area of compressed gum cud (SA) SA = nr2 where: SA = surface area of compressed gum (m2) r = radius of compressed gum cud disc (m) 3) compression ratio (c)
where: c = compression ratio rs = radius of spherical gum cud (m), equation 1 r = average radius of gum cud after compression (m) 4) compression modulus (G)
where: G = compression modulus (kPa) m = mass of compression force (Kg) g = weight force acceleration due to gravity (9.8 m/s2) SA = surface area of compressed gum cud (m2), equation 2 c = compression ratio, equation 3 [0019] In another embodiment, the chewing gum composition releases greater than or equal to 90% of the total weight of biologically active ingredient into the oral cavity during a 30 minute chewing cycle. Suitably, the chewing gum composition releases greater than or equal to 95% of the total weight of biologically active ingredient into the oral cavity during a 30 minute chewing cycle. In another embodiment, the chewing gum composition releases greater than or equal to 99% of the total weight of biologically active ingredient into the oral cavity during a 30 minute chewing cycle. Nicotine release values quoted herein were determined using EP 7th Ed dissolution apparatus b, using 1.6 mm jaw gap, 40“ rotation, 40 chews min, 37 “C temperature, 40 ml. mastication medium (pH6 phosphate buffer).
[0020] The chewing gum compositions are composed of a water-insoluble chewable gum base portion, a water-soluble bulk portion comprising actives and/or flavours. During chewing the water soluble bulk portion is dissolved in saliva and dissipates out of the gum, into the oral cavity taking with it a portion of the active and/ or flavour. The water-insoluble gum base portion remains in the oral cavity for the duration of the chew.
[0021] The term ‘chewing gum’ is used in its broadest sense and encompasses both chewing gum and bubble gum.
[0022] The gum base (or gumbase) is the water-insoluble masticatory substance of the composition and is generally composed of elastomers, resins, plasticisers and water insoluble adjuvant other optional components including antioxidants and colourants. Some gum bases may include amphiphilic or degradable polymers to minimise chewing gum littler pollution in the environment.
[0023] The amount of gum base used in the composition will vary depending on a number of factors such as the type of gum base used, the weight of the final chewing gum, the desired gum cud (bolus) size and other components of the chewing gum. In an embodiment, the gum base is present in amounts from 5 to 90% by weight of the total gum composition. Suitably, the gum base is present in amounts from 15 to 80% by weight of the total gum composition. More suitably, the gum base is present in amounts from 40 to 75% by weight of the total gum composition. Even more suitably, the gum base is present in amounts from 50 to 60% by weight of the total gum composition. Most suitably, the gum base is present in amounts from 52 to 58% by weight of the total gum composition.
[0024] The gum base may comprise 1 to 70% by weight of an elastomeric material, based on the total weight of the gum base. The elastomeric material provides desirable elasticity and textural properties as well as bulk. The elastomer may be any water-insoluble polymer known in the art, including gum polymers for chewing gum and bubble gum listed in Food and Drug Administration, CFR, Title 21, Section 172.615 as “Masticatory Substances of Natural Vegetable Origin” and “Masticatory Substances, Synthetic”. Details of typical synthetic elastomeric polymers used in gum base are given in Chapter 4, ‘Formulation and Production of Chewing Gum and Bubble Gum’ Ed Douglas Fritz (2006) pp. 93-118 and is included herein for reference.
[0025] In an embodiment, the elastomeric material selected from one or more of arabic gum, smoked or liquid latex (Hevea brasiliensis), chicle, crown gum, balata, gutta kay, gutta hang kang, gutta-percha, jelutong, lechi-capsi, massaranduba, massaranduba chocolate, niger gutta, nispero, perillo, rosadinha, sorva, tunu and the like, polyisobutylene, butadiene-styrene copolymer and isobutylene-isoprene copolymer.
[0026] Butadiene styrene rubber (SBR) is a non-linear, random copolymer composed of styrene and butadiene monomer units. Typically the ratio of styrene to butadiene is in the range of 20:80 through to 60:40 styrene: butadiene with a molecular weight less than 600,000 g/mol. Butyl rubber (isobutylene-isoprene copolymer) is a branched polymer composed of isoprene (2-methyl-1,3-butadiene) monomer units copolymerised with isobutylene (2-methylpropene) monomer. Typically the molecular weight of butyl rubber in chewing gum base is in the range 150.000 g/mol to 1,000,000 g/mol. Polyisobuytylene rubber (PIB) is a branched polymeric elastomer obtained by polymerisation of isobutylene (2-methylpropene). It is available in a wide range of molecular weights; medium molecular weight grades range between 36,000 g/mol to 75.000 g/mol. The high molecular weight grades are available in a range between 200,000 g/mol to 4,100,000 g/mol.
[0027] Suitably, the elastomeric material is selected from: a. A mixture of isobutylene-isoprene copolymer and polyisobutylene, wherein the polyisobutylene has a molecular weight of 36,000 to 75,000 g/mol; or b. A mixture of a first polyisobutylene having a molecular weight of 36,000 to 75.000 g/mol and a second polyisobutylene having a molecular weight of 200.000 to 4,100,000 g/mol.
[0028] In an embodiment, the elastomeric material is present in an amount from 5 to 20% of the total weight of the gum base. Suitably, the elastomeric material is present in an amount from 7 to 15% of the total weight of the gum base.
[0029] The gum base may comprise 5 to 70% by weight of an elastomer plasticiser, based on the total weight of the gum base. Elastomer plasticisers (also known as elastomer solvents) aid in softening the elastomeric material. Examples of elastomer plasticisers suitable for use in the chewing gum base of the present invention include the pentaerythritol ester of partially hydrogenated wood rosin, pentaerythritol ester of wood rosin, glycerol ester of partially dimerized rosin, glycerol ester of polymerised rosin, glycerol ester of tall oil rosin, glycerol ester of wood rosin and partially hydrogenated wood rosin and partially hydrogenated methyl ester of rosin; terpene resins derived from d-limonene, α-pinene or β-pinene and mixtures thereof. In an embodiment, the gum base comprises an elastomer plasticiser selected from one or more of methyl glycerol, a pentaerythritol ester of a rosin or a modified rosin, and a terpene resin derived from d-limonene, α-pinene or β-pinene. Suitably, the elastomer plasticiser is a terpene resin derived from d-limonene.
[0030] In an embodiment, the elastomer plasticiser is present in an amount from 15 to 30% of the total weight of the gum base.
[0031] The gum base may comprise 15 to 45% by weight of a non-toxic vinyl polymer, based on the total weight of the gum base. Such polymers may have some affinity for water. In an embodiment, the gum base comprises a non-toxic vinyl polymer selected from one or more of poly(vinyl acetate), ethylene acetate, vinyl acetate and a copolymer of vinyl laurate and vinyl acetate. Suitably, the non-toxic vinyl polymer is poly(vinyl acetate).
[0032] The non-toxic vinyl polymer should have a molecular weight of at least 2000. Suitably, the non-toxic vinyl polymer should have a molecular weight between 10,000 and 55,000. Unless otherwise specified, the unit of molecular weight used in this specification is g/mol.
[0033] In an embodiment, the non-toxic vinyl polymer is present in an amount from 20 to 30% of the total weight of the gum base.
[0034] The gum base may comprise 0 to 40% by weight of a filler, based on the total weight of the gum base. The filler (also known as a water-insoluble adjuvant) is preferably a particulate filler. Fillers are used to modify the texture of the gum base and aid in its processing. In an embodiment, the gum base comprises a filler selected from one or more of calcium carbonate, talc, amorphous silica, tricalcium phosphate, magnesium carbonate, alumina, aluminium hydroxide and aluminium silicate. Suitably, the filler is talc, or calcium carbonate.
[0035] The size of the filler particle has an effect on cohesiveness, density and processing characteristics of the gum base on compounding. The mean particle size for talc and calcium carbonate fillers are suitably in the range from about 0.1 micron to about 15 microns.
[0036] In an embodiment, the filler is present in an amount from 5 to 25% of the total weight of the gum base. Suitably, the filler is present in an amount from 12 to 22% of the total weight of the gum base. More suitably, the filler is present in an amount from 16 to 20% of the total weight of the gum base.
[0037] The gum base may comprise 15 to 40% by weight of a softener or emulsifier, based on the total weight of the gum base. Softeners are used to regulate cohesiveness, to modify the texture and to introduce sharp melting transitions during chewing of a product. Softeners ensure thorough blending of the gum base and may further plasticize the elastomers of the gum base. Emulsifiers aid in dispersing the immiscible components of the chewing gum composition into a single stable system. In an embodiment, the gum base comprises at least one softener or emulsifier selected from one or more of hydrogenated vegetable oils, lanolin, stearic acid, sodium stearate, potassium stearate, glycerine, lecithin, glycerol, glycerol monooleate, lactylic esters of fatty acids, lactylated fatty acid esters of glycerol and propylene glycol, mono-, di-, and tri-stearyl acetates, monoglyceride citrate, stearic acid, stearyl monoglyceridyl citrate, stearyl-2-lactylic acid, triacyetyl glycerin, triethyl citrate and polyethylene glycol. Suitably, the softener or emulsifier is selected from one or more of hydrogenated vegetable oils, acetic acid esters of monoglycerides, lecithin and glycerol monostearate.
[0038] In an embodiment, the softener or emulsifier is present in an amount from 18 to 25% of the total weight of the gum base.
[0039] The gum base may comprise 0.04 to 0.09% by weight of an antioxidant, based on the total weight of the gum base. Antioxidants prolong the shelf life of gum base and the resulting gums including fats and flavourings. In an embodiment, the gum base comprises an antioxidant selected from butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), tocopherol, betacarotenes, propyl gallate and an acidulants (e.g. vitamin C). Suitably, the antioxidant is butylated hydroxytoluene.
[0040] The water-soluble portion of the chewing gum may be composed of ingredients such as bulk sweeteners, softeners, high-intensity sweeteners, flavouring agents, acidulents, sensates to provide cooling, warming or tingling sensations, pharmaceutical actives, nutraceutical actives, herbal extracts, stimulants, fragrances, microencapsulates, abrasives, whitening agents, buffers, colouring agents, fillers, antioxidants, actives and any other components required to give the desired sensory attributes.
[0041] In an embodiment, the biologically active ingredient can be a breath freshener, a dental care component, a biologically active material, an effervescing system, an appetite suppressant, a vitamin, a mineral, a nutritional supplement, a micronutrient, a nutraceutical, a mouth moistening component, a throat care active, an energy or concentration boosting component or any combination thereof.
[0042] In another embodiment, the biologically active ingredient is any substance which modifies a chemical or physical process in the human or animal body. Suitably, the biologically active ingredient is a pharmaceutically active ingredient and is, for instance, selected from antiplatelet aggregation drugs, erectile dysfunction drugs, decongestants, anaesthetics, oral contraceptives, cancer chemotherapeutics, psychotherapeutic agents, cardiovascular agents, NSAID's, NO Donors for angina, non-opioid analgesics, antibacterial drugs, antacids, diuretics, anti-emetics, antihistamines, anti-inflammatories, antitussives, anti-diabetic agents (for instance, insulin), opioids, hormones and combinations thereof. More suitably, the active ingredient is a stimulant such as caffeine or nicotine. Alternatively, the active ingredient is an analgesic. A further example of an active ingredient is insulin.
[0043] In another embodiment of the invention, the biologically active ingredient is a nonsteroidal anti-inflammatory drug (NSAID), such as diclofenac, ketoprofen, ibuprofen or aspirin. Alternatively the active ingredient is paracetamol (which is generally not classed as an NSAID).
[0044] The biologically active ingredient may be an anti-emetic, for instance Dolasetron. Alternatively the biologically active ingredient is an erectile dysfunction drug, such as sildenafil citrate.
[0045] The biologically active ingredient may be any alkaloid chemical compound having a wide range of pharmacological activity such as antimalaria, antiasthma, anticancer, cholinomimetic, vasodilatory, antiarrhythmic, analgesic, antibacterial or antihyperglycemic properties.
[0046] In a particular embodiment, the biologically active ingredient is a ‘tobacco alkaloid’, including nicotine and nicotine-like alkaloids that may be in a free-base form or any pharmaceutically acceptable salt form. Suitably, the biologically active ingredient is nicotine. Nicotine may be bound as a salt to a suitable complex or compound. The nicotine may be bound to a cation exchange resin containing suitable acidic groups. Suitable acidic groups may be carboxylic, sulfonic, phosphoric, and phenolic acid. The ion exchange resin may be composed of cross-linked polymers of styrene and divinylbenzene, divinylbenzene and methacrylic acid or acrylic acid and the like. Applicable ion exchange resins are described in US Patent No.3,845,217 & US Patent No. 3,901,248 and are included herein for reference. The nicotine may also be stabilised by reversible adsorption onto an inorganic mineral filler such as calcium carbonate as described in US patent applications US 2012/ 0039981 and US 2012/ 0321751 and included here for reference. The preferred ion exchange resin for nicotine is a weakly acidic cation exchange resin of methacrylic acid and divinylbenzene sold as Amberlite IRP-64.
[0047] The quantity of biologically active ingredient will depend on the desired therapeutic effect. In an embodiment, the chewing gum composition comprises 0.1 to 5% by weight of nicotine, based on the total weight of the chewing gum composition. Suitably, the chewing gum composition comprises 0.1 to 1% by weight of nicotine, based on the total weight of the chewing gum composition. More suitably, the chewing gum composition comprises 0.2 to 0.6% by weight of nicotine, based on the total weight of the chewing gum composition.
[0048] The chewing gum composition may also comprise one or more buffers (pH adjusting agent) present in a quantity of 0.1 to 10% by weight of the total chewing gum composition. Suitably, the one or more buffers is present in a quantity of 0.5 to 5% by weight of the total chewing gum composition. More suitably, the one or more buffers is present in a quantity of 2 to 4% by weight of the total chewing gum composition. The buffers should elevate the pH of saliva in the mouth to the range of about 7.5 to about 10, preferably in the range of about 8 to about 9.5. The buffers should be delivered to the oral cavity at a rate appropriate for optimal maintenance of the salivary pH whilst the active ingredient (e.g. nicotine) is released from the chewing gum to the mouth. Nicotine chewing gum often contain pH adjusting agents to optimise the absorption of nicotine across the buccal cavity. This is done by raising the pH of the buccal cavity above normal mouth pH to convert ionised nicotine into the unionised form which will readily cross the buccal membrane allowing direct delivery of the nicotine into the bloodstream (avoiding hepatic first pass effect).
[0049] In an embodiment, the buffer is selected from one or more of sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium hydroxide, magnesium oxide, potassium citrate and sodium glycinate. Suitably, the buffer is selected from sodium carbonate, sodium hydrogen carbonate, potassium carbonate and potassium hydrogen carbonate.
[0050] Depending on the desired release of the buffers from the gum the buffers may be encapsulated to delay or prolong the delivery time from the gum mass to the oral cavity. Encapsulation techniques such as wax granulation, wet granulation, spray drying, spray chilling, fluid bed coating, coascervation and fibre extrusion may all be employed. US patent application US 2012/0087875 describes a method of incorporating the buffers into the gum base to modify the release and is included herein for reference.
[0051] The at least one sweetening or flavouring agent of the chewing gum composition may comprise one or more bulk sweeteners. Bulk sweeteners include both sugar and sugar-free components. Bulk sweeteners often act as bulking agents whilst improving the juiciness and aiding the flavour profile of the chewing gum. In an embodiment, the bulk sweetener is present in an amount from 5 to 90% of the total weight of the chewing gum composition. Suitably, the bulk sweetener is present in an amount from 20 to 80% of the total weight of the chewing gum composition. More suitably, the bulk sweetener is present in an amount from 30 to 60% of the total weight of the chewing gum composition. Even more suitably, the bulk sweetener is present in an amount from 30 to 45% of the total weight of the uncoated chewing gum composition. Most suitably, the bulk sweetener is present in an amount from 32 to 42% of the total weight of the uncoated chewing gum composition.
[0052] In an embodiment, the bulk sweetener is selected from one or more of sucrose, dextrose, glucose syrup, hydrogenated glucose syrup, fructose, corn syrup solids, maltose, levulose, saccharose, lactose, galactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, sorbitol, mannitol, xylitol, maltitol, isomalt and erythritol.
[0053] The at least one sweetening or flavouring agent of the chewing gum composition may comprise one or more high intensity sweeteners. Depending on the sweetness and flavour profile desired for the chewing gum product, bulk sweeteners may be used in combination with high intensity sweeteners. Suitable high intensity sweeteners include but are not limited to aspartame, acesulfame K, alitame, cyclamic acid and its salts, dihydrochalacones, glycyrrhizin, monellin, saccharin and its salts, sucralose, thaumatin and similar. The high intensity sweeteners may be encapsulated to prolong the sweetness delivery and flavour perception. Techniques such as spray drying, fluid bed coating, spray chilling, wet granulation, coascervation, wax granulation, and fibre extrusion may all be employed to tune the release rate.
[0054] Suitably, the high intensity sweetener is one or more of aspartame, acesulfame K and sucralose.
[0055] In an embodiment, the high intensity sweetener is present in an amount from 0.01 to 10% of the total weight of the chewing gum composition. Suitably, the high intensity sweetener is present in an amount from 0.5 to 1.5% of the total weight of the chewing gum composition.
[0056] The at least one sweetening or flavouring agent of the chewing gum composition may be a flavouring agent. Chewing gums will typically contain flavours, these may be of synthetic or natural origin may be in liquid or solid form, they may be essential oils, natural components, whole cells, essences, extracts, powders etc. Patent US 2015/0201644 Al include a wide range of possible flavour oils, aldehydes and esters, sensates, warming agents, tingling agents, effervescence agents and colouring agents that may be incorporated into chewy confectionery and gum and is included herein for reference. In an embodiment, the chewing gum composition comprises a flavouring agent in a quantity of 0.1 to 10% by weight of the chewing gum composition. Suitably, the chewing gum composition comprises a flavouring agent in a quantity of 3 to 7% by weight of the chewing gum composition. More suitably, the chewing gum composition comprises a flavouring agent in a quantity of 4 to 6% by weight of the chewing gum composition.
[0057] The chewing gum composition of the present invention may have a coating (e.g. a crunchy chewing gum coating). Any suitably coating composition may be used. In an embodiment, the coating is present in a quantity of 20-25% by weight, based on the total weight of the coated chewing gum composition.
[0058] In an embodiment, the coating comprises a crystallisable sweetener, gum arabic, high intensity sweetener and inorganics. Suitably, the coating comprises 90 to 95 wt% of crystallisable sweetener, 0.5 to 4 wt% gum arabic, 0.1 to 2 wt% high intensity sweetener, and 0.5 to 3 wt% inorganic materials [0059] In a particular embodiment, the coating contains 90 to 95 wt% of crystallisable sweetener, 1 to 3 wt% gum arabic, 0.4 to 1 wt% high intensity sweetener, 0.5 to 1.5 wt% Ti02, and 0.4 to 1 wt% CaCC>3.
[0060] In another embodiment, the chewing gum composition may comprise a biodegradable polymer.
[0061] The following numbered paragraphs describe particular embodiments of the chewing gum compositions of the present invention: 1) 40-75wt% of a gum base, 0.1-2wt% of a biologically active ingredient 0.001-0.1 wt% of a colourant 20-80wt% of a bulk sweetener 0.01-5wt% of a high intensity sweetener 1 -10wt% of a flavouring 0.5-5wt% of a buffer 2) 50-65wt% of a gum base, 0.1-1wt% of a biologically active ingredient 0.001 -0.5wt% of a colourant 30-60wt% of a bulk sweetener 0.1-5wt% of a high intensity sweetener 1 -10wt% of a flavouring 1 -5wt% of a buffer 3) 50-60wt% of a gum base, 0.1-1wt% of a ‘tobacco alkaloid’, including nicotine and nicotine-like alkaloids 0.001 -0.5wt% of a colourant 30-60wt% of a bulk sweetener 0.1-5wt% of a high intensity sweetener 1 -10wt% of a flavouring 1 -5wt% of a buffer 4) 50-60wt% of a gum base, of which 7-15wt% is an elastomeric material 10-50wt% is a mixture of a non-toxic vinyl polymer, a softener and an emulsifier 15-30wt% is an elastomer plasticiser 15-25wt% is a filler 0.04-0.09wt% is an antioxidant 0.1-1wt% of a ‘tobacco alkaloid’, including nicotine and nicotine-like alkaloids 0.001 -0.5wt% of a colourant 30-60wt% of a bulk sweetener 0.1-5wt% of a high intensity sweetener 1 -10wt% of a flavouring 1 -5wt% of a buffer 5) 50-60wt% of a gum base, of which 7-15wt% is an elastomeric material 30-50wt% is a mixture of a non-toxic vinyl polymer, a softener and an emulsifier 20-30wt% is an elastomer plasticiser 15-25wt% is a filler 0.04-0.09wt% is an antioxidant 0.1-0.8wt% of a ‘tobacco alkaloid’, including nicotine and nicotine-like alkaloids 0.001-0.1 wt% of a colourant 30-45wt% of a bulk sweetener 0.1-3wt% of a high intensity sweetener 3-7wt% of a flavouring 1 -5wt% of a buffer 6) 50-60wt% of a gum base, of which 7-15wt% is an elastomeric material selected from i) A mixture of isobutylene-isoprene copolymer and polyisobutylene, wherein the polyisobutylene has a molecular weight of 36,000 to 75,000 g/mol; or ii) A mixture of a first polyisobutylene having a molecular weight of 36,000 to 75,000 g/mol and a second polyisobutylene having a molecular weight of 200,000 to 4,100,000 g/mol 30-50wt% is a mixture of a non-toxic vinyl polymer, a softener and an emulsifier 20-30wt% is an elastomer plasticiser that is a terpene resin derived from d-limonene 15-25wt% is a filler selected from is talc or calcium carbonate 0.04-0.09wt% is a butylated hydroxytoluene antioxidant 0.1-0.8wt% of a ‘tobacco alkaloid’, including nicotine and nicotine-like alkaloids 0.001-0.1 wt% of a colourant 30-45wt% of a bulk sweetener selected from one or more of sucrose, dextrose, glucose syrup, hydrogenated glucose syrup, fructose, corn syrup solids, maltose, levulose, saccharose, lactose, galactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, sorbitol, mannitol, xylitol, maltitol, isomalt and erythritol. 0.1-3wt% of a high intensity sweetener selected from one or more of aspartame, acesulfame K and sucralose 3-7wt% of a flavouring 1-5wt% of a buffer selected from sodium carbonate, sodium hydrogen carbonate, potassium carbonate and potassium hydrogen carbonate 7) 52-58wt% of a gum base, of which 7-15wt% is an elastomeric material selected from i) A mixture of isobutylene-isoprene copolymer and polyisobutylene, wherein the polyisobutylene has a molecular weight of 36,000 to 75,000 g/mol; or ii) A mixture of a first polyisobutylene having a molecular weight of 36,000 to 75,000 g/mol and a second polyisobutylene having a molecular weight of 200,000 to 4,100,000 g/mol 40-50wt% is a mixture of a non-toxic vinyl polymer, a softener and an emulsifier 20-30wt% is an elastomer plasticiser that is a terpene resin derived from d-limonene 15-22wt% is a filler selected from is talc or calcium carbonate 0.04-0.09wt% is a butylated hydroxytoluene antioxidant 0.1-0.6wt% of a ‘tobacco alkaloid’, including nicotine and nicotine-like alkaloids 0.005-0.1wt% of a colourant 32-42wt% of a bulk sweetener selected from one or more of sucrose, dextrose, glucose syrup, hydrogenated glucose syrup, fructose, corn syrup solids, maltose, levulose, saccharose, lactose, galactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, sorbitol, mannitol, xylitol, maltitol, isomalt and erythritol. 0.5-2wt% of a high intensity sweetener selected from one or more of aspartame, acesulfame K and sucralose 3-7wt% of a flavouring 1-5wt% of a buffer selected from sodium carbonate, sodium hydrogen carbonate, potassium carbonate and potassium hydrogen carbonate
Preparation of chewing gum compositions [0062] As discussed hereinbefore, the present invention also provides a process for the preparation of the chewing gum composition of any preceding claim, the process comprising the step of: a) mixing, until homogenous, the gum base, at least one biologically active ingredient and at least one sweetening or flavouring agent.
[0063] In an embodiment, step a) is conducted at a temperature of 20 to 80°C. Suitably, step a) is conducted at a temperature of 40 to 60^ [0064] In another embodiment, step a) comprises for following sequential steps: a1) adding the at least one active ingredient, a2) adding the gum base, and a3) adding the at least one sweetening or flavouring agent, wherein steps a1, a2 and a3 are performed with mixing.
[0065] Chewing gum may be manufactured by adding the ingredients step-wise into a sigma or z-blade mixer or other suitable mixer such as a twin-screw extruder. One the chewing gum mixture is homogenous the gum mass is discharged from the mixer and formed into the desired size and shape, this may be by rolling into sheets and cutting into sticks or by extruding into chunks or casting into pellets.
[0066] In general the chewing gum base is warmed to a pliable consistency either before or after addition to the mixer - colours and actives may be added at this stage. Addition of bulk and high intensity sweetener, syrup and softener may be added early in the mix process, further portions of the bulk sweetener(s) may be added to the mixture once the first addition was incorporated. Flavouring agents may be added with the final portion of the bulk sweetener. Buffers may be added with the bulk sweetener at any stage.
[0067] A chewing gum mixing process typically takes about 5 to 15 minutes but can take longer. Variations to the above procedure maybe used, a one step process is described in US patent application 2004/0115305 and included herein for reference.
[0068] In accordance with the present invention the chewing gum may take any form or structure, such as pellet, a stick, a ball, a chunk, a tablet, a pill, a pastille or a sphere. The chewing gum may be center filled with liquid or solid.
[0069] In an embodiment, the process may comprise an additional step b) of coating the chewing gum composition. The chewing gum core may constitute 0.1 to 75% of the coated chewing gum weight. Suitable coatings include hard coatings, soft coatings and film coatings. The coating may be sugar or sugar-free. The preferred coating is a hard coating. A hard coating gives a sweet, crunchy layer that improves the consumer experience and protects the cores from environment stresses such as ingress of moisture. It will be understood that any of the coating compositions defined herein may be used.
[0070] A sugar crunchy coating may be prepared with any suitable crystallisable sugar such as sucrose or dextrose. Alternatively the coating may be prepared with non-cariogenic, crystallisable sweeteners such as sorbitol, xylitol, maltitol, mannitol, erythritol, isomalt, lactitol or tagatose.
[0071] The coating may also contain functional ingredients such as colours, flavours, pharmaceutical actives and teeth whitening components.
[0072] A hard coating is prepared by the application of a syrup containing crystallisable sweetener (sugar or polyol) to the cores in a rotating drum. The water from the syrup is driven off by cool air and low humidity and the sweetener crystallises onto the surface of the cores, this addition of the syrup is repeated numerous times, typically 3 to 80, to build up the coating size or weight to that desired.
[0073] A film coating may be applied to the chewing gum cores, the film is generally one or more film forming polymers, the film coating may also contain plasticizers, pigments, opacifiers, colours, waxes and saccharide compounds. Typically a film coating is 20-1 OOprn thick and applied by spraying the cores with atomised droplets of the coating solution. The film is built up in layers with the film forming spray being allowed to dry on the cores before the next application of the coating solution. This process is repeated until the desired coating thickness is achieved.
[0074] Suitable polymers for the film coating include edible cellulose derivatives such as methyl cellulose (MC), hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC). Acrylic polymers and copolymers and mixtures of acrylate polymers and cellulose derivatives may be used.
[0075] In another embodiment, prior to step a), the gum base is prepared by a process comprising the step of: i) mixing, until homogenous, one or more elastomeric materials, one or more non-toxic vinyl polymers, one or more elastomer plasticisers, one or more fillers, one or more antioxidants, and one or more emulsifiers or softening agents.
[0076] Suitably, step (i) is conducted at a temperature of 100 to 150 °C. More suitably, step (i) is conducted at a temperature of 110 to 130 °C.
[0077] In another embodiment, step (i) comprises the following sequential steps: ia) adding the one or more elastomeric materials, ib) adding the one or more elastomer plasticisers and one or more fillers, ic) adding the one or more non-toxic vinyl polymers id) adding the one or more antioxidants and one or more emulsifiers or softening agents, wherein steps ia, ib, ic and id are performed with mixing.
[0078] Preparation of a gum base may be performed in a z-blade or sigma-blade mixer operating at a temperature in the region of 105 to 120 “C. The initial part of the gum base manufacture sequence is compounding; formation of a homogenous mass of the elastomer, elastomer plasticizer and filler. Once the compounding of the elastomers has been completed the remainder of the gum base manufacture is homogenisation of the vinyl polymers, softeners, emulsifiers and antioxidant.
[0079] In an initial compounding stage, all of the elastomer and a portion of the elastomer plasticizer and filler, such as about one third of the elastomer plasticiser and filler, may be added to the mixer. The exact amount of elastomer plasticizer and filler added to the mixer at this stage is determined by the batch size, the mixer size and dimensions. The ingredients are mixed for anywhere between about 15 and 90 minutes depending on the exact nature of the ingredients; such as the molecular weight of the elastomers, the mixer efficiency and the desired final consistency of the gum base. After the initial ingredients are homogenised and compounded the remaining portions of the elastomer plasticizer and filler are added and mixed until homogenous. Typically this initial homogenisation of the elastomer with elastomer plasticizer and filler will take up to one hour. The second stage of gum base manufacture is incorporation and homogenisation of the remaining gum base ingredients such as vinyl polymer, softener, emulsifier and antioxidant. Each of these ingredients is incorporated in portions and the contents of the mixer homogenised prior to subsequent additions. This second stage of ingredient addition typically takes about 60 minutes, with the gum base mass being allowed to become homogenous before discharge from the mixer.
[0080] In an embodiment, the finished gum base is filtered through a mesh (200 microns minimum) to ensure the absence of undesirable particles either raw materials or contamination during manufacture. The molten gum base mass is discharged into coated or lined pans, extruded or cast into any desirable shape and allowed to cool and solidify. Those skilled in the art will recognise that there are variations to the above procedure that would be suitable for the production of a suitable gum base.
[0081] Gum base can be produced using continuous mixing for example in a twin-screw extruder (US 6,010,723) or as an automated continuous production (US 6,017,565); as compressible gum base granules (US 8,734,763)and as part of a one-step process (US 2004/ 0,115,305), these patents are hereby incorporated for reference.
[0082] The preparation of the chewing gum base, chewing gum core and coated gum may use any of the equipment commonly reported in the art for said purpose. A useful guide to methods for manufacturing chewing gum and ingredients suitable for incorporation therein may be found in ‘Formulation and Production of Chewing Gum and Bubble Gum’ Ed Douglas Fritz (2006), the contents of which is incorporated by way of example.
[0083] A common measurement used for characterising the properties of the gum base is softening point. The softening point of the gum base as measured by the ring and ball method; well known to those skilled in the art. In a particular embodiment of the invention, the softening point of the gum base is 45“C to 65“C. Suitably, the softening point of the gum base is 50“C to 60“C.
EXAMPLES
[0084] Examples of the invention will now be described, for the purpose of illustration only, with reference to the accompanying figure, in which:
Fig. 1 shows the hardness, at set time points during a 30 minute chew cycle, of Commercial gum 1 and Inventive Gum 3 (described in Example 4) chewed gum cuds. Values are reported in Example 7.
Methods and materials
Ingredients [0085] All ingredients were obtained from standard suppliers of ingredients for use in chewing gum and used without further purification.
Reference Chewing Gum (Commercial 1) [0086] A standard commercial nicotine gum, Nicorette Original Flavor uncoated 4 mg gum obtained from retail stores in the USA, was used as the control in the experiments. This product is the Reference Listed Drug for nicotine gum in the U.S. Food and Drug Administration’s reference guide (FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations) and thus an appropriate standard for the experiments. It will be referred to as Commercial 1 in the Examples below.
Reference method A: Drug release tests on medicated chewing gums [0087] Nicotine release is measured using a method based on that described in the European Pharmacopoeia. The gum sample is masticated using mechanical chewing apparatus (EP approved dissolution apparatus B) and the samples analysed using reverse phase HPLC based on the method described in the European Pharmacopoeia.
Preparation of phosphate buffer [0088] Weigh 34 g ±0.1 g potassium dihydrogen orthophosphate into a beaker. Add approximately 2 L purified water and sonicate using an ultrasonic bath until the potassium dihydrogen orthophosphate has completely dissolved. Fill the beaker to approx 4.0 L. Using a calibrated pH meter measure the pH of the phosphate buffer. Adjust the pH of the phosphate buffer slowly to 6.0 using 1.0M potassium hydroxide. Transfer to 5 L volumetric flask, dilute to volume with purified water and mix thoroughly.
Preparation of Ammonium Dihydrogen Orthophosphate Buffer Solution [0089] Weigh 11.5 g ± 0.1 g ammonium dihydrogen orthophosphate and transfer to a 2 L beaker. Add approximately 300 mL purified water and sonicate using an ultrasonic bath until the ammonium dihydrogen orthophosphate has completely dissolved. Adjust pH to 8.5 using ammonium hydroxide. Transfer contents of the 2 L beaker into a 2L volumetric flask, dilute to volume with purified water and mix thoroughly.
Procedure for Analysing the Release Profiles of Active Ingredients from Gum [0090] Each piece of gum was weighed before chewing, and the weight recorded to allow estimation of the total quantity of drug in each piece.
[0091] A ERWEKA DRT-1 chewing apparatus (European Pharmacopoeia 7th Edition approved dissolution apparatus B) from AB FIA was used, which operates by alternately compressing and twisting the gum in between two mesh grids. A water jacket, with the water temperature set to 37 °C was used to regulate the temperature in the mastication cell to match that expected when chewed in vivo, and the chew rate was set to 40 ‘chews’ per minute. The parameters used in mastication are summarised below in Table 1.
Table 1: Chewing Parameters
[0092] 40 ml. phosphate buffer was added to the mastication cell, then a plastic mesh placed at its bottom. A piece of gum of known weight was placed on the centre of the mesh, and a second piece of mesh put on top. At the start of each run, the cell containing the artificial saliva and gum was left for 5 minutes so that the system could equilibrate to 37 °C. The gum was then masticated. A sample volume of 0.5 ml. was then withdrawn from the test cell after mastication for analysis.
[0093] All the samples were then analysed by HPLC using a Agilent 1100 Series High Performance Liquid Chromatography system, equipped with an autosampler, pump, and diode array detector. Data handling and instrument control was provided via ChemStation software. Gemini NX, 3pm, C18 (2), 100A, 50mm x 4.6mm columns were used. The mobile phase was a mixture of 75% (v/v) ammonium dihydrogen orthophosphate buffer solution (5.4) and 25% (v/v) acetonitrile. The flow rate was 1 mL/min and column temperature was 40 °C. A UV detector set to monitor a wavelength of 260 nm was used for analysis.
Reference method B: Comparison of the chew profiles of gum [0094] To determine the chew profile of a gum, it is chewed by volunteers for a set period of time, removed from the mouth and the mass of the gum cud recorded. The gum cud is then immediately transferred to a non-compressible surface and subjected to a known force. The diameter of the compressed gum cud is measured and recorded. The mass, diameter and compression force are used to calculate the compression modulus which is a measure of the hardness of the chewing gum at that chew time.
[0095] A gum piece is given to a volunteer with instructions to chew the gum for a set period of time. Once the gum has been chewed for the predetermined time the gum cud is removed from the mouth, excess saliva removed and the mass of the gum cud recorded. The gum cud is immediately transferred to a level, non-compressible surface, covered with a wet, nylon disc and compressed using a known mass, for example by a person standing on the nylon disc covering the gum cud for 10 s. The nylon disc is removed from the gum cud and the diameter of the gum cud is measured using a calibrated vernier caliper gauge or a ruler. Ideally at least two readings of the diameter, perpendicular to each other, are recorded and averaged to give a representative indication of the compressed gum cud size. Ideally replicate samples of each gum are chewed for each time point of the chew profile. Standard time points for the chew profile are 1, 2, 3, 5, 10, 20 and 30 minutes. The region of greatest change of gum hardness are early in the chew, so more time points are collected in this region. Nicotine gum patient information leaflets advise chewing the gum until most of the tingle is gone (about 30 minutes).. As such the experiment concluded after 30 minutes chewing. 1) radius of sphere (rs)
where: rs = radius of spherical gum cud (m)
V = volume (g) and assume density of gum cud = 1; d=m/V 2) surface area of compressed gum cud (SA) SA = nr2 where: SA = surface area of compressed gum (m2) r = radius of compressed gum cud disc (m) 3) compression ratio (c)
where: c = compression ratio rs = radius of spherical gum cud (m), equation 1 r = average radius of gum cud after compression (m) 4) compression modulus (G)
where: G = compression modulus (kPa) m = mass of compression force (Kg) g = weight force acceleration due to gravity (9.8 m/s2) SA = surface area of compressed gum cud (m2), equation 2 c = compression ratio, equation 3
The average results of these calculations for each gum cud at each time point may be plotted on an appropriate graph to give a visual representation of the chew profile of a chewing gum.
Example 1 - Preparation of gum base [0096] A gum base is prepared composed of the ingredients listed in Table 2 below:
Table 2: Gum base Ingredients
[0097] Exemplary elastomers are i) A mixture of isobutylene-isoprene copolymer and polyisobutylene, wherein the polyisobutylene has a molecular weight of 36,000 to 75,000 g/mol; and ii) A mixture of a first polyisobutylene having a molecular weight of 36,000 to 75,000 g/mol and a second polyisobutylene having a molecular weight of 200,000 to 4,100,000 g/mol.
[0098] The resin is composed of non-toxic vinyl polymer, softener and emulsifier. Exemplary resin components are poly(vinyl acetate) (molecular weight between 10,000 and 55,000 g/mol), hydrogenated vegetable oils, acetic acid esters of monoglycerides, lecithin and glycerol monostearate.
[0099] Exemplary plasticisers are polyterpene resins derived from d-limonene.
[00100] Exemplary fillers (water insoluble adjuvant) are talc and calcium carbonate.
[00101] An exemplary antioxidant is BHT.
[00102] Any suitable heated mixing vessel may be used for the preparation of gum base, in this instance a z-blade mixer which has been heated to 120 “C. The elastomer is cut into small pieces before adding to the mixer where it is softened by the heat and mechanical action of the z-blades. The elastomer plasticizer and water insoluble adjuvant is added in approximate one-third portions and homogenised over a period of approximately 30 to 50 minutes. The resin is added to the mixer in portions over about 10 to 20 minutes and mixed until homogenised. The softening ingredients are then added portion-wise over the next 20 to 40 minutes and mixed until homogenous. The full gum base mixing process will take approximately 60 to 120 minutes. The molten gum base mixer is removed from the mixer and allowed to cool to room temperature.
Example 2 - Preparation of uncoated gum core (Gum 1) [00103] Nicotine chewing gum is prepared using the gum base of Example 1, the chewing gum is prepared in a conventional mechanical mixer with moderate heat applied. The composition of the chewing gum core is described in Table 3 below.
Table 3: Chewing Gum Ingredients Used to Make Gum 1
[00104] Exemplary bulk sweeteners are sucrose, dextrose, glucose syrup, hydrogenated glucose syrup, fructose, corn syrup solids, maltose, levulose, saccharose, lactose, galactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, sorbitol, mannitol, xylitol, maltitol, isomalt and erythritol.
[00105] Exemplary high intensity sweeteners are aspartame, acesulfame K and sucralose.
[00106] Exemplary buffers are sodium carbonate, sodium hydrogen carbonate, potassium carbonate and potassium hydrogen carbonate.
[00107] Nicotine chewing gum is typically prepared in a z-blade mixer, heated to approximately 50“C. The gum base may be warmed to soften it prior to addition to the mixer.
Components of the chewing gum added to the mixer in portions to ensure a homogenous mixture. The active component is added to the gum base at the start and a premix of defined duration is performed to ensure thorough mixing. Flavour components are added towards the end of the mixing process to minimise the time that volatile components are exposed to heat. Mixing procedures may last from 5 to 15 minutes but may take longer.
[00108] After discharge from the mixer the chewing gum is formed into approximately 1 g pieces containing 4 mg of nicotine.
Example 3 - Preparation of uncoated gum core (Gum 2) [00109] Nicotine chewing gum is prepared using the gum base of Example 1, the chewing gum is prepared in a conventional mechanical mixer with moderate heat applied. The composition of the chewing gum core is described in Table 4 below.
Table 4: Chewing Gum Ingredients Used to Make Gum 2
[00110] Exemplary bulk sweeteners are sucrose, dextrose, glucose syrup, hydrogenated glucose syrup, fructose, corn syrup solids, maltose, levulose, saccharose, lactose, galactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, sorbitol, mannitol, xylitol, maltitol, isomalt and erythritol.
[00111] Exemplary high intensity sweeteners are aspartame, acesulfame K and sucralose.
[00112] Exemplary buffers are sodium carbonate, sodium hydrogen carbonate, potassium carbonate and potassium hydrogen carbonate.
[00113] Nicotine chewing gum is typically prepared in a z-blade mixer, heated to approximately 50“C. The gum base may be warmed to soften it prior to addition to the mixer. Components of the chewing gum added to the mixer in portions to ensure a homogenous mixture. The active component is added to the gum base at the start and a premix of defined duration is performed to ensure thorough mixing. Flavour components are added towards the end of the mixing process to minimise the time that volatile components are exposed to heat. Mixing procedures may last from 5 to 15 minutes but may take longer.
[00114] After discharge from the mixer the chewing gum is formed into approximately 1 g pieces containing 2 mg of nicotine.
Example 4 - Preparation of uncoated gum core (Gum 3) [00115] Chewing gum is prepared using the gum base of Example 1; the chewing gum is prepared in a conventional mechanical mixer with moderate heat applied. The composition of the chewing gum core is described in Table 5 below. The preparation procedure is the same as described for Example 2.
Table 5: Chewing Gum Ingredients Used to Make Gum 3
[00116] Exemplary bulk sweeteners are sucrose, dextrose, glucose syrup, hydrogenated glucose syrup, fructose, corn syrup solids, maltose, levulose, saccharose, lactose, galactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, sorbitol, mannitol, xylitol, maltitol, isomalt and erythritol.
[00117] Exemplary high intensity sweeteners are aspartame, acesulfame K and sucralose.
[00118] Exemplary buffers are sodium carbonate, sodium hydrogen carbonate, potassium carbonate and potassium hydrogen carbonate.
[00119] After discharge from the mixer the chewing gum is formed into approximately 1 g pieces. These gums were essentially identical to those made in Example 2 (Gum 1), with the exception that they didn’t contain nicotine and were found to have very similar physical properties. The absence of nicotine allowed them to be chewed by non-smokers as described in Example 7.
Example 5 - Preparation of coated nicotine gum (Gum 4) [00120] Coated chewing gums are prepared using the uncoated chewing gum in Example 2 as the gum cores using a conventional coating technique in a rotating coating pan. The coating composition is described in Table 6 below.
Table 6: Chewing Gum Ingredients Used to Make the Coating on Gum 4
[00121] A syrup containing a crystallisable sweetener, gum arabic solution, high intensity sweetener and inorganics is prepared and added to the cores step-wise to create a number of layers, the coating will typically be built up over approximately 3 to 80 layers. Crunchy chewing gum coatings are applied using a coating pan or drum familiar to those skilled in the art. The coating layers are built up around the chewing gum core to compose approximately 20-25% of the final coated chewing gum mass.
Example 6 - Preparation of coated nicotine gum (Gum 5) [00122] Coated chewing gums are prepared using the uncoated chewing gum in Example 3 as the gum cores using a conventional coating technique in a rotating coating pan. The coating composition is described in Table 7 below.
Table 7: Chewing Gum Ingredients Used to Make the Coating on Gum 5
[00123] A syrup containing a crystallisable sweetener, gum arabic solution, high intensity sweetener and inorganics is prepared and added to the cores step-wise to create a number of layers, the coating will typically be built up over approximately 3 to 80 layers. Crunchy chewing gum coatings are applied using a coating pan or drum familiar to those skilled in the art. The coating layers are built up around the chewing gum core to compose approximately 20-25% of the final coated chewing gum mass.
Example 7 - Comparison of the chew profiles [00124] The chew profile of samples of a commercial nicotine chewing gum and Inventive Gum 3 (Example 4) were evaluated using the procedure described in Reference Method B (Table 8).
Table 8: Chew Profile of Inventive and Non-lnventive Gum
[00125] As will be observed from Fig. 1, the inventive gum sample was found to be significantly softer than the commercial standard, and showed a compression modulus of approximately <5 kPa for the duration of the 30 minute chew regime, thus giving rise to a more pleasant chew.
Example 8 - Comparison of release [00126] Samples of the commercial nicotine chewing gum, Inventive Gum 4 containing 4 mg nicotine (Example 5) and inventive gum 5 containing 2 mg nicotine (Example 6) were masticated for 30 minutes and the amount of nicotine released after 30 minutes analysed using the method described in Reference Method A (Table 9).
Table 9: Nicotine Release Profile of Inventive and Non-lnventive Gum
[00127] Whilst only 62% of the nicotine active had been released after 30 minutes from the commercial gum, a total of 96% had been released from inventive Gum 4 after this period of time and 93% had been released from inventive Gum 5.
[00128] While specific embodiments of the invention have been described herein for the purpose of reference and illustration, various modifications will be apparent to a person skilled in the art without departing from the scope of the invention as defined by the appended claims.
Claims (44)
1. A chewing gum composition comprising a chewing gum base, at least one biologically active ingredient and at least one sweetening or flavouring agent, wherein the chewing gum composition has a compression modulus of less than 7 kPa.
2. The chewing gum composition of claim 1, wherein the chewing gum composition has a compression modulus of 1.5 to 6 kPa.
3. The chewing gum composition of claim 1 or 2, wherein the chewing gum composition has a compression modulus of 3 to 6 kPa.
4. The chewing gum composition of any of claims 1,2 or 3, wherein the gum base is present in an amount from 40 to 75% of the total weight of the chewing gum composition.
5. The chewing gum composition of any preceding claim, wherein the gum base is present in an amount from 50 to 60% of the total weight of the chewing gum composition.
6. The chewing gum composition of any preceding claim, wherein the gum base is present in an amount from 52 to 58% of the total weight of the chewing gum composition.
7. The chewing gum composition of any preceding claim, wherein the at least one sweetening or flavouring agent comprises a bulk sweetener present in an amount from 30 to 60% of the total weight of the chewing gum composition.
8. The chewing gum composition of claim 7, wherein the bulk sweetener is selected from one or more of sucrose, dextrose, glucose syrup, hydrogenated glucose syrup, fructose, corn syrup solids, maltose, levulose, saccharose, lactose, galactose, sorbose, dextrin, trehalose, D-tagatose, dried invert sugar, sorbitol, mannitol, xylitol, maltitol, isomalt and erythritol.
9. The chewing gum composition of any preceding claim, wherein the at least one sweetening or flavouring agent comprises a high intensity sweetener present in an amount from 0.01 to 10% of the total weight of the chewing gum composition.
10. The chewing gum composition of claim 9, wherein the high intensity sweetener is selected from one or more of aspartame, acesulfame K, alitame, cyclamic acid and its salts, dihydrochalacones, glycyrrhizin, monellin, saccharin and its salts, sucralose and thaumatin.
11. The chewing gum composition of claim 10, wherein the high intensity sweetener is selected from one or more of aspartame, acesulfame K and sucralose.
12. The chewing gum composition of any preceding claim, wherein the gum base comprises an elastomeric material selected from one or more of arabic gum, smoked or liquid latex (Hevea brasiliensis), chicle, crown gum, balata, gutta kay, gutta hang kang, gutta-percha, jelutong, lechi-capsi, massaranduba, massaranduba chocolate, niger gutta, nispero, perillo, rosadinha, sorva, tunu and the like, polyisobutylene, butadiene-styrene copolymer and isobutylene-isoprene copolymer.
13. The chewing gum composition of claim 12, wherein the elastomeric material is selected from: a. A mixture of isobutylene-isoprene copolymer and polyisobutylene, wherein the polyisobutylene has a molecular weight of 36,000 to 75,000 g/mol; or b. A mixture of a first polyisobutylene having a molecular weight of 36,000 to 75.000 g/mol and a second polyisobutylene having a molecular weight of 200.000 to 4,100,000 g/mol.
14. The chewing gum composition of claim 12 or 13, wherein the elastomeric material is present in an amount from 7 to 15% of the total weight of the gum base.
15. The chewing gum composition of any preceding claim, wherein the gum base comprises an elastomer plasticiser selected from one or more of methyl glycerol, a pentaerythritol ester of a rosin or a modified rosin, and a terpene resin derived from d-limonene, α-pinene or β-pinene.
16. The chewing gum composition of claim 15, wherein the elastomer plasticiser is a terpene resin derived from d-limonene.
17. The chewing gum composition of claim 15 or 16, wherein the elastomer plasticiser is present in an amount from 15 to 30% of the total weight of the gum base.
18. The chewing gum composition of any preceding claim, wherein the gum base comprises a non-toxic vinyl polymer selected from one or more of poly(vinyl acetate), ethylene acetate, vinyl acetate and a copolymer of vinyl laurate and vinyl acetate.
19. The chewing gum composition of claim 18, wherein the non-toxic vinyl polymer is poly(vinyl acetate).
20. The chewing gum composition of claim 18 or 19, wherein the non-toxic vinyl polymer is present in an amount from 20 to 30% of the total weight of the gum base.
21. The chewing gum composition of any preceding claim, wherein the gum base comprises a filler selected from one or more of calcium carbonate, talc, amorphous silica, tricalcium phosphate, magnesium carbonate, alumina, aluminium hydroxide and aluminium silicate.
22. The chewing gum composition of claim 21, wherein the filler is a particulate filler having an average particle size of 0.1 to 15 pm.
23. The chewing gum composition of claim 21 or 22, wherein the filler is talc or calcium carbonate.
24. The chewing gum composition of claim 21,22 or 23, wherein the filler is present in an amount from 12 to 22% of the total weight of the gum base.
25. The chewing gum composition of any preceding claim, wherein the gum base comprises at least one softener or emulsifier selected from one or more of hydrogenated vegetable oils, lanolin, stearic acid, sodium stearate, potassium stearate, glycerine, lecithin, glycerol, glycerol monooleate, lactylic esters of fatty acids, lactylated fatty acid esters of glycerol and propylene glycol, mono-, di-, and tri-stearyl acetates, monoglyceride citrate, stearic acid, stearyl monoglyceridyl citrate, stearyl-2-lactylic acid, triacyetyl glycerin, triethyl citrate and polyethylene glycol.
26. The chewing gum composition of claim 25, wherein the softener or emulsifier is selected from one or more of hydrogenated vegetable oils, acetic acid esters of monoglycerides, lecithin and glycerol monostearate.
27. The chewing gum composition of claim 25 or 26, wherein the softener or emulsifier is present in an amount from 18 to 25% of the total weight of the gum base.
28. The chewing gum composition of any preceding claim, wherein the gum base comprises an antioxidant selected from butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), tocopherol, betacarotenes, propyl gallate and an acidulants (e.g. vitamin C).
29. The chewing gum composition of claim 28, wherein the antioxidant is butylated hydroxytoluene.
30. The chewing gum composition of claim 28 or 29, wherein the antioxidant is present in an amount from 0.06 to 0.09% of the total weight of the gum base.
31. The chewing gum composition of any preceding claim, wherein the chewing gum composition further comprises a buffer selected from one or more of sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium hydroxide, magnesium oxide, potassium citrate and sodium glycinate.
32. The chewing gum composition of claim 31, wherein the buffer is selected from sodium carbonate, sodium hydrogen carbonate, potassium carbonate and potassium hydrogen carbonate.
33. The chewing gum composition of claim 31 or 32, wherein the buffer is present in an amount from 2 to 4% of the total weight of the chewing gum composition.
34. The chewing gum composition of any preceding claim, wherein the biologically active ingredient is a tobacco alkaloid (e.g. nicotine).
35. The chewing gum composition of any preceding claim, wherein, over the course of a 30 minute chewing cycle, the chewing gum releases greater than or equal to 85% by weight of the total quantity of active ingredient contained therein prior to chewing.
36. The chewing gum composition of any preceding claim, wherein, over the course of a 30 minute chewing cycle, the chewing gum releases greater than or equal to 90% by weight of the total quantity of active ingredient contained therein prior to chewing..
37. The chewing gum composition of any preceding claim, wherein, over the course of a 30 minute chewing cycle, the chewing gum releases greater than or equal to 95% by weight of the total quantity of active ingredient contained therein prior to chewing..
38. The chewing gum composition of claims 35 to 37, wherein the release of the biologically active ingredient is measured using a European Pharmacopoeia 7th Edition dissolution apparatus b, and using the following parameters: jaw gap of 1.6 mm 40“ rotation 40 chews per minute 37 “C temperature 40 ml. mastication medium (pH6 phosphate buffer).
39. A process for the preparation of the chewing gum composition of any preceding claim, the process comprising the step of: a. mixing, until homogenous, the gum base, at least one biologically active ingredient and at least one sweetening or flavouring agent.
40. The process of claim 39, wherein step a) is conducted at a temperature of 20 to 80^.
41. The process of claim 39 or 40, wherein step a) comprises for following sequential steps: a1) adding the at least one active ingredient, a2) adding the gum base, and a3) adding the at least one sweetening or flavouring agent, wherein steps a1, a2 and a3 are performed with mixing.
42. The process of any of claims 39, 40 or 41, wherein prior to step a), the gum base is prepared by a process comprising the step of: i) mixing, until homogenous, one or more elastomeric materials, one or more non-toxic vinyl polymers, one or more elastomer plasticisers, one or more fillers, one or more antioxidants, and one or more emulsifiers or softening agents.
43. The process of claim 42, wherein step (i) is conducted at a temperature of 100 to 150 °C.
44. The process of claim 42 or 43, wherein step (i) comprises the following sequential steps: ia) adding the one or more elastomeric materials, ib) adding the one or more elastomer plasticisers and one or more fillers, ic) adding the one or more non-toxic vinyl polymers id) adding the one or more antioxidants and one or more emulsifiers or softening agents, wherein steps ia, ib, ic and id are performed with mixing.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1516153.2A GB2542192A (en) | 2015-09-11 | 2015-09-11 | Chewable medicament |
| PCT/GB2016/052816 WO2017042592A1 (en) | 2015-09-11 | 2016-09-12 | Chewable medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1516153.2A GB2542192A (en) | 2015-09-11 | 2015-09-11 | Chewable medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201516153D0 GB201516153D0 (en) | 2015-10-28 |
| GB2542192A true GB2542192A (en) | 2017-03-15 |
Family
ID=54363055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1516153.2A Withdrawn GB2542192A (en) | 2015-09-11 | 2015-09-11 | Chewable medicament |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2542192A (en) |
| WO (1) | WO2017042592A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190290684A1 (en) * | 2018-03-23 | 2019-09-26 | Fertin Pharma A/S | Solid pharmaceutical tablet |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585115A (en) * | 2019-11-01 | 2019-12-20 | 慧生医学科技(徐州)有限公司 | Soft chewing medicinal composition and preparation method thereof |
| WO2025059444A1 (en) * | 2023-09-15 | 2025-03-20 | Wm. Wrigley Jr. Company | Chewing gum base compositions and methods of use and making the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991006288A1 (en) * | 1989-11-07 | 1991-05-16 | Anders Dam | A nicotine containing stimulant unit |
| US20060121093A1 (en) * | 1999-04-06 | 2006-06-08 | Ream Ronald L | Tableted products including active agent |
| US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020098264A1 (en) * | 1998-11-27 | 2002-07-25 | Cherukuri Subraman R. | Medicated chewing gum delivery system for nicotine |
| AU2004264949B2 (en) * | 2003-08-14 | 2011-04-14 | Cargill, Incorporated | Chewing gum compositions comprising monatin and methods of making same |
| BRPI0808122A2 (en) * | 2007-02-26 | 2014-06-17 | Revolymer Ltd | Medical Chewing Gum |
| WO2012083947A1 (en) * | 2010-12-21 | 2012-06-28 | Fertin Pharma A/S | Chewing gum composition comprising cross-linked polyacrylic acid |
| CA2852788C (en) * | 2011-10-19 | 2019-02-12 | Fertin Pharma A/S | Nicotine chewing gum with improved utilization of nicotine |
| WO2015154780A1 (en) * | 2014-04-08 | 2015-10-15 | Fertin Pharma A/S | Medical chewing gum |
-
2015
- 2015-09-11 GB GB1516153.2A patent/GB2542192A/en not_active Withdrawn
-
2016
- 2016-09-12 WO PCT/GB2016/052816 patent/WO2017042592A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991006288A1 (en) * | 1989-11-07 | 1991-05-16 | Anders Dam | A nicotine containing stimulant unit |
| US20060121093A1 (en) * | 1999-04-06 | 2006-06-08 | Ream Ronald L | Tableted products including active agent |
| US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190290684A1 (en) * | 2018-03-23 | 2019-09-26 | Fertin Pharma A/S | Solid pharmaceutical tablet |
| US10980831B2 (en) * | 2018-03-23 | 2021-04-20 | Fertin Pharma A/S | Solid pharmaceutical tablet |
| US20210205355A1 (en) * | 2018-03-23 | 2021-07-08 | Fertin Pharma A/S | Solid pharmaceutical tablet |
| US11723918B2 (en) * | 2018-03-23 | 2023-08-15 | Fertin Pharma A/S | Solid pharmaceutical tablet |
| US11730757B2 (en) | 2018-03-23 | 2023-08-22 | Fertin Pharma A/S | Solid pharmaceutical tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201516153D0 (en) | 2015-10-28 |
| WO2017042592A1 (en) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6627234B1 (en) | Method of producing active agent coated chewing gum products | |
| US6949264B1 (en) | Nutraceuticals or nutritional supplements and method of making | |
| JP5437574B2 (en) | Tobacco alkaloid releasing chewing gum | |
| CA2589489C (en) | Method of providing fast relief to a user of a nicotine chewing gum | |
| JP5469006B2 (en) | Flavoring-containing chewing gum delivery composition | |
| WO2000035296A1 (en) | Improved release of medicament active agents from a chewing gum coating | |
| US20030021830A1 (en) | Chewable product including active ingredient | |
| Maggi et al. | Preparation and evaluation of release characteristics of 3TabGum, a novel chewing device | |
| JP5437692B2 (en) | Chewing gum composition, chewing gum product, and methods for producing them | |
| EP1408933A2 (en) | Sildenafil citrate chewing gum formulations and methods of using the same | |
| WO2017042592A1 (en) | Chewable medicament | |
| Jadhav et al. | A comprehensive review on: medicated chewing gum | |
| AU2024202892B2 (en) | A solid pharmaceutical tablet | |
| CA2355779C (en) | Improved release of medicament active agents from a chewing gum coating | |
| Daharwal et al. | Chewing Gum as Novel Approach for Delivery of Medicament: A Review | |
| JP2011057701A (en) | Method to give rapid alleviation for nicotine chewing gum user |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |